Growth Runway

Growth Runway

The 'breadth carries growth' answer held in FY2025 — livestock +8% and diagnostics +13% lifted group organic growth to +6% while US companion growth flattened — but in Q1 FY2026 the weakness spread into the newer companion franchises meant to be the offset (key dermatology −11%, Librela −13%, OA-pain mAbs −8%), pulling companion animal down 4% and testing whether the diversified portfolio can still carry the group. [1][2][3][4]

FY2025's group +6% organic growth rested on livestock +8% and diagnostics +13% carrying a flat US companion engine. In Q1 FY2026 the newer companion franchises meant to be the offset themselves declined, so companion animal fell 4% [5]; if diagnostics, livestock, and international also roll over, the FY2026 2–5% organic guide becomes the ceiling rather than the floor [6]. The offset is bending, not broken: companion-animal diagnostics still grew 10% and livestock 12% in Q1 FY2026, and neither shares the US pet-visit cycle that is pulling companion animal down [7] [8].

Zoetis's forward growth does not depend on the mature US companion-animal market that stalled in 2025. Animal health globally is still a mid-to-high-single-digit grower, and Zoetis carries a pipeline of 12 products each targeted at $100 million or more of annual sales [9], alongside diagnostics and livestock franchises compounding at double digits. The feared flagship patent cliff is years out. The case is most sensitive to how fast pipeline breadth offsets US category maturity while the largest US categories digest competition.

A growing industry, unevenly

The secular case for animal health is old and durable, and Zoetis has been describing it the same way since its 2013 carve-out: rising pet ownership and spending, companion animals living longer and receiving more medical treatment, and a growing global appetite for animal protein [10]. At the IPO, the companion-animal medicines and vaccines sector was growing at roughly a 6% compound rate [11]. More than a decade later, third-party forecasters still put the whole industry on a mid-to-high-single-digit path.

Sources: third-party market-research forecasts (Grand View Research; Precedence Research; Towards Healthcare; Market.us), compiled July 2026; segment definitions and base years differ across providers, so treat the levels as indicative rather than precise.

Two cautions attach to that table. The forecasts come from commercial research houses, not the filings, and their dispersion is wide — base-year estimates for the total market run from the low-$60-billions to the high-$60-billions depending on scope. And the growth is uneven. The part of the industry that stalled for Zoetis — US companion-animal spending — is the mature part, where clinic traffic has fallen for four straight years (Demand Diagnosis). The industry's growth vectors sit mostly elsewhere: emerging-market companion adoption, diagnostics, and livestock. Reading Zoetis as a slowing business means reading it through its most mature geography; the runway is a question of mix.

Breadth beyond the flagship

Zoetis is more diversified than its US parasiticide-and-dermatology reputation suggests, and 2025 showed the value of that spread. Group revenue grew 6% organically (4 points price, 2 points volume) even as the US companion engine faltered; companion animal grew 5% operationally, livestock 8%, and companion-animal diagnostics 13% [12] [13].

Source: Q4 FY2025 earnings call, prepared remarks [14] [15].

Diagnostics is the quieter of the two offsets and the more interesting. It grew 13% through a year of falling clinic visits [16], because a diagnostic instrument, once placed, pulls recurring consumable and reference-lab revenue that is only loosely tied to visit counts — the opposite of the visit-sensitive parasiticide dynamic in Demand Diagnosis. Third-party forecasters see animal diagnostics compounding at roughly 10% into the mid-2030s, and Zoetis is expanding the platform through in-clinic launches, AI-enabled imaging, and a next-generation chemistry system due in 2026.

Livestock carries its own secular story, distinct from companion demand. Management frames it around global protein consumption rising with income, a US demand tailwind from GLP-1 use and updated nutritional guidance, and an industry-wide shift from treating disease to preventing it [17]. Whether those tailwinds fully arrive is uncertain, but the point for the growth runway is structural: the livestock, diagnostics, and international companion businesses do not share the US pet-visit cycle, so a stalled US flagship does not stall the whole company.

The pipeline

The reacceleration case rests on innovation, and Zoetis funds it consistently. Research and development spending rose from $614 million in 2023 to $698 million in 2025, holding around 7% of revenue through the slowdown [18]. Management's stated output is a pipeline of 12 potential blockbusters — its own bar for that word is $100 million or more of annual revenue — including candidates that open entirely new categories of care [19].

Source: FY2025 10-K, MD&A [20]; pipeline count per Q4 FY2025 earnings call [21].

The engine has two gears. The first is lifecycle innovation — extending an existing molecule with new species, claims, combinations, and formulations — which is how the Simparica franchise grew into a $1.5 billion, 12%-growth business through the Simparica Trio triple-combination, and how Apoquel was reformulated into a chewable [22]. The second is new-category creation: the osteoarthritis-pain monoclonal antibodies Librela and Solensia, a long-acting successor in development, and the diagnostics platform. Both gears feed the same historical formula management has repeated on nearly every call — grow faster than the market [23]. At its 2022 investor day, Zoetis pegged its largest category, parasiticides, at $6.3 billion in 2022 growing to $10–12 billion by 2032, and expected to outgrow that pool [24].

That formula met its first real US test in early 2026. Where a category is still expanding — international companion, livestock, diagnostics — the innovation-led share-gain model still works. Where a category stopped expanding, as US parasiticides and dermatology did, branded rivals took share directly out of Zoetis's base rather than out of new market growth (Franchise Moat). The pipeline's job has therefore shifted: less about taking share in growing pools, more about opening new pools fast enough to replace a maturing flagship. Twelve blockbuster candidates is a credible answer on paper; none has yet been proven at scale, and management's own framing has moved from growth "driven by new product cycles" toward a more measured tone.

The patent question, reframed

The word "cliff" hangs over any patent-protected drug company, but for Zoetis's companion flagships the near-term reality is milder than the label implies. The 10-K's patent-expiry disclosures name only older livestock and legacy products — tulathromycin (Draxxin), the ceftiofur line, and Cerenia's formulation patents running to 2025–2028. The filings are silent on the timing for Apoquel and Simparica. Third-party patent trackers fill that gap: the core compound patent for Apoquel's oclacitinib runs to roughly 2030, and Simparica's sarolaner to roughly 2032, with reformulations and combinations (Apoquel Chewable, Simparica Trio) layering further protection on top. Both drugs' original FDA marketing exclusivities have already lapsed, so the flagships are patent-defended but no longer exclusivity-defended.

Sources: legacy expiries per FY2025 10-K, Intellectual Property [25]; companion-flagship compound-patent dates per third-party patent trackers (Greyb/Pharsight), not company disclosure.

The more important point is structural: in animal health, loss of exclusivity is a slow bleed, not a step change. Unlike human pharma, there is no large, well-capitalized generic company competing globally, because each product opportunity is smaller and distribution runs directly through veterinarians who prescribe and dispense on a mostly self-pay basis [26]. Zoetis's portfolio still carries more than 5,500 granted patents and 1,600 pending [27], and the company argues that brand loyalty typically persists after patents lapse [28]. The contrast with human pharma is stark: a large-cap human drugmaker can lose the bulk of a product's sales within a year or two of a biosimilar entering. Animal-health erosion plays out over many years.

That slow bleed is real, not painless. The precedent inside Zoetis's own portfolio is Draxxin, which lost roughly two-thirds of its US sales to generics after patents expired (Franchise Moat), and generic Cerenia has already been approved in the US. And the near-term threat to the companion flagships is not generics at all — it is branded competitors launching directly against Simparica and Apoquel while their patents are still in force. For the growth runway, that reframes the risk usefully: the pressure on Zoetis over the next three to five years is competitive and cyclical, not a wave of expiring exclusivity.

What would change the read

The evidence points to a growth runway that is real at the industry and portfolio level. Animal health remains a sunrise sector globally; Zoetis's diagnostics, livestock, and international companion businesses grew through a year that broke its US flagship; the funded pipeline is broad; and the flagship patents run to the end of the decade and beyond. On the balance of evidence, the industry- and portfolio-level runway is intact; the open question is the pace at which new pipeline converts while the largest, most mature category digests competition.

The strongest fact against that read is that the "grow faster than the market" formula just failed its first genuine US test, 2026 guidance of 2–5% sits below the algorithm's historical output [29], and not one of the 12 blockbuster candidates has yet proven it can carry a franchise the way Simparica Trio did.

What would resolve it, in either direction, is observable. On the constructive side: new-category launches crossing the $100 million threshold, US companion demand stabilizing, and diagnostics and livestock sustaining double-digit growth. On the other: a second guidance cut, flagship share loss accelerating, or the pipeline slipping. Those are the markers that separate a temporary air pocket from a structurally slower compounder — and they will show up in the quarterly numbers long before they show up in the multiple.